Grant✓ Small businesses may apply
Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
National Institutes of Health
- Opportunity #
- PAR-25-064
- Agency
- National Institutes of Health
- ALN (CFDA)
- 93.866, 93.242
- Status
- posted
- Posted
- Nov 18, 2024
- Closes
- Sep 7, 2026
- Funding instrument
- Grant
- Category
- Health
- Cost sharing required
- No
Who can apply
- •Native American tribal governments (Federally recognized)
- •Public housing authorities/Indian housing authorities
- •Public and State controlled institutions of higher education
- •State governments
- •County governments
- •Small businesses
- •Independent school districts
- •Native American tribal organizations (other than Federally recognized tribal governments)
- •Others (see text field entitled "Additional Information on Eligibility" for clarification)
- •Special district governments
- •Private institutions of higher education
- •For profit organizations other than small businesses
- •Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- •City or township governments
- •Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Synopsis
The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advanceadavnce mechanistic understanding of both biobehavioral and neurobiologfical pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD.
Contact
National Institutes of Health · grantsinfo@nih.gov